Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3

Charlotte Hind, Melanie Clifford, Charlotte Woolley, Jane Harmer, Leah McGee, Izaak Tyson-Hirst, Henry Tait, Daniel Brooke, Stephanie Dancer, Iain Hunter, Colin Suckling, Rebecca Beveridge, John Parkinson, J.Mark Sutton, Fraser Scott

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


MGB-BP-3 is a potential first-in-class antibiotic, a Strathclyde Minor Groove Binder (S-MGB), that has successfully completed Phase IIa clinical trials for the treatment of Clostridioides difficile associated disease. Its precise mechanism of action and the origin of limited activity against Gram-negative pathogens are relatively unknown. Herein, treatment with MGB-BP-3 alone significantly inhibited the bacterial growth of the Gram-positive, but not Gram-negative, bacteria as expected. Synergy assays revealed that inefficient intracellular accumulation, through both permeation and efflux, is the likely reason for lack of Gram-negative activity. MGB-BP-3 has strong interactions with its intracellular target, DNA, in both Gram-negative and Gram-positive bacteria, revealed through ultraviolet–visible (UV–vis) thermal melting and fluorescence intercalator displacement assays. MGB-BP-3 was confirmed to bind to dsDNA as a dimer using nano-electrospray ionization mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy. Type II bacterial topoisomerase inhibition assays revealed that MGB-BP-3 was able to interfere with the supercoiling action of gyrase and the relaxation and decatenation actions of topoisomerase IV of both Staphylococcus aureus and Escherichia coli. However, no evidence of stabilization of the cleavage complexes was observed, such as for fluoroquinolones, confirmed by a lack of induction of DSBs and the SOS response in E. coli reporter strains. These results highlight additional mechanisms of action of MGB-BP-3, including interference of the action of type II bacterial topoisomerases. While MGB-BP-3′s lack of Gram-negative activity was confirmed, and an understanding of this presented, the recognition that MGB-BP-3 can target DNA of Gram-negative organisms will enable further iterations of design to achieve a Gram-negative active S-MGB.
Original languageEnglish
Pages (from-to)2552-2563
Number of pages12
JournalACS Infectious Diseases
Issue number12
Early online date29 Nov 2022
Publication statusPublished - 9 Dec 2022


Dive into the research topics of 'Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3'. Together they form a unique fingerprint.

Cite this